# Patent

## Title
Use of mannosamine derivatives for the stimulation of neurite growth

## Abstract

The present invention relates to the use of peracylated N-acyl-mannosamine derivatives for the preparation of a medicament for stimulating neurite growth.

## Background
CROSS REFERENCE TO RELATED APPLICATIONS
The present application claims priority to German Application No. 10147382.6, filed Sep. 26, 2001 and German Application No. 10203308.0, filed Jan. 29, 2002, which applications are incorporated herein fully by this reference.
The present invention relates to the use of N-acyl-mannosamine derivatives, especially N-propanoyl-1,3,4,6-O-tetraacetylmannosamine and N-cyclopropyl-carbonyl-1,3,4,6-O-tetracyclopropylcarbonylmannosamine for the stimulation of neurite growth.
BACKGROUND OF THE INVENTION
Sialic acids are carbohydrates which form a family of about 40 naturally occurring derivatives of neuraminic acid and which all except one are N-acylated (Schauer et al., 1995; Varki, 1992). They are distinguished from another by N and/or O substituents. N substituents are primarily acetyl and glycolyl groups. O substituents are, among others, acetyl, lactoyl, methyl, sulfate and phosphate groups. The most abundant representative of sialic acids is N-acetylneuraminic acid (NeuNAc), which is the precursor of all other sialic acids. Sialic acids are the terminal monosaccharides of complex N-glycans and many O-glycanes of glycoproteins as well as gangliosides.
By different modifications and binding types, the neuraminic acids contribute to the structural variety of glycoconjugates and have a great influence on numerous biological processes.
While sialinic acids play an important role in various biological processes, until recently, nothing was known about the importance of their N-acetyl or N-glycolyl side chain in these processes. The physiological precursor of all natural sialinic acids is N-acetylmannosamine. By the application of non-physiological N-acyl-mannosamines or glucosamines whose side chain is extended by one or more methylene groups, the corresponding neuraminic acids are biosynthesized (Grunholz et. al., 1981; Kayser et al. 1992).
A precursor such as N-propanoylmannosamine (ManNProp) is metabolized into N-propanoylneuraminates and subsequently, as N-propanoyineuraminic acid (NeuNProp), it is incorporated into the membrane proteins of the cells as well as into the serum glycoproteins (gangliosides) (Kayser et al., 1992).
Cell culture experiments have shown that biological processes such as viral infections and cell proliferation are permanently influenced by thus modified neuraminic acids.
DE 197 38 484 discloses the use of N-propanoylmannosamine, N-isopropanoyl-mannosamine and/or N-cyclopropanoylmannosamine (i.e., more correctly, N-cyclopropylcarbonylmannosamine) for the preparation of a medicament for myelinization and remyelinization. The capability of the above mentioned mannosamine derivatives of effecting myelinization and remyelinization is based on their property of being stimulators of oligodendrocytes.
Further, WO 00/07602 describes that particular N-acylmannosamines (such as N-acetyl-, N-propanoyl-, N-glycolyl-, N-formylmannosamine) are suitable for the modulation of neuronal growth or for the enhancement or inhibition of neurite growth. However, these compounds have the drawback that their effectiveness is rather low. On the other hand, WO 00/07602 also discloses O-acylated derivatives of the above mentioned compounds; in particular, N-glycolylmannosamine pentaacetate is mentioned. However, all the glycolylmannosamine derivatives have the drawback of being antigenic.
Surprisingly, it has been found that special N- and O-acylated mannosamine compounds can stimulate neurite growth significantly better as compared to the compounds of WO 00/07602. N-propanoyl- and N-cyclopropylcarbonyltetra-acetylmannosamine have proven particularly suitable (among the non-O-acylated compounds N-propanoylmannosamine has been found to be most effective.
SUMMARY OF THE INVENTION
Therefore, the present invention relates to

    (1) the use of N-acylmannosamine derivatives of formula (I)






wherein

    R is an acyl residue, especially an acetyl (—CO—CH3), propanoyl (—CO—C2H5), butanoyl (—CO—C3H7), pentanoyl (—CO—C4H9), hexanoyl (—CO—C5H11), cyclopropyl-carbonyl (—CO—C3H5), crotonoyl (—CO—CH═CH—CH3), levulinoyl (—CO—CH2—CH2—CO—CH3) or azidoacetyl residue (—CO—CH2—N3); and
    each R1 independently represents an acyl residue, especially an acetyl residue; for the preparation of a medicament for stimulating neurite growth;
    (2) a compound of formula (I), wherein R is a cyclopropylcarbonyl residue, and R1 represent acyl residues;
    (3) a pharmaceutical composition comprising the compound defined in (2) above;
    (4) a process for the preparation of the compound defined in (2) above, comprising the reacting of mannosamine with an activated cyclopropylcarbonyl compound; and
    (5) a method for stimulating neurite growth in mammals, especially humans, comprising administration of an acylmannosamine derivative as defined in (1) to said mammals (preferably to humans).





BRIEF DESCRIPTION OF THE FIGURES
The invention is further illustrated by the following FIGS. 1 to 3:
FIG. 1: On collagen I, PC12 cells were incubated for two days with 100 ng of NGF, followed by fixation and staining.
FIG. 2: On collagen I, PC12 cells were incubated for two days with 100 ng of NGF and 5 mM N-propanoylmannosamine, followed by fixation and staining.
FIG. 3 shows the influence of the addition of N-propanoylmannosamine on neurite formation.



DETAILED DESCRIPTION OF THE INVENTION
According to the present invention, the term “mannosamine derivatives” comprises all derivatives of mannosamine familiar to the skilled person which are derived from this compound and which contain “mannosamine” in their names. The mannosamine derivatives comprise both D and L forms of mannosamine, and a mixture of the D and L forms. Also included are the pure α and β anomers of the mannosamine derivatives and mixtures thereof.
In the mannosamine compound of formula (1), the acyl residue in the definition of R1 may be any acyl residue familiar to the skilled person. However, it is preferred that R1, like R, is an acetyl, propanoyl (—CO—C2H5), butanoyl (—CO—C3H7), pentanoyl (—CO—C4H9), hexanoyl (—CO—C5H11), cyclopropylcarbonyl (—CO—C3H5), crotonoyl (—CO—CH═CH—CH3), levulinoyl (—CO—CH2—CH2—CO—CH3) or azido-acetyl residue (—CO—CH2—N3), wherein R is more preferably a propanoyl, isopropanoyl, butanoyl or cyclopropylcarbonyl residue, and R1 are acetyl residues.
According to the present invention, the residues comprise butanoyl (—CO—C3H7), pentanoyl (—CO—C4H9) and hexanoyl (—CO—C5H11), and in addition to the unbranched residues also their constitutional isomers known to the skilled person, such as isobutanoyl (—CO—CH—(CH3)2), isopentanoyl (—CO—CH2—CH(CH3)2), 2-methylbutanoyl (—CO—CH(CH3)—C2H5) etc.
Further, according to the present invention, the term “crotonoyl” (—CO—CH═CH—CH3) comprises the two possible geometric isomers, i.e., both the E and the Z forms, which are known to the skilled person.
In a special embodiment of (1), 1-N-propanoyl-3,4,6-O-tetraacetylmannosamine is employed for the stimulation of neurite growth.
The formulation of the medicament according to the invention for stimulating neurite growth according to (1) or the formulation of the pharmaceutical composition (3) may be effected by methods known to the skilled person.
In addition to the compound of formula (I), these medicaments/compositions may also contain other pharmaceutically acceptable compounds which are familiar to the skilled person, such as carriers, diluents, etc.
The medicaments (1) are suitable for the treatment of CNS-neurodegenerative diseases, especially Alzheimer's and Parkinson's diseases. Similarly, the method (5) is suitable for treating said diseases.
The pharmaceutical composition (3) can be employed both for the stimulation of neurite growth and for myelinization and remyelinization (see DE-A-197 38 484). In addition, the compounds (2) may also be employed for the preparation of recombinant glycoproteins as described in WO 00/29567.
The preparation process according to embodiment (4) of the invention comprises the reaction of the mannosamine with an activated cyclopropylcarbonyl compound. Then, to prepare pentacyclopropylcarbonylmannosamine, purification of the product from the reaction mixture of this (first) acylation step is immediately effected. If derivatives are desired in which acyl residues other than cyclopropyl-carbonyl are present, a mild saponification of the reaction mixture is first effected, followed by a second acylation step with suitable activated acyl derivatives. Suitable activated acyl compounds and cyclopropylcarbonyl compounds include anhydrides, acid anhydrides, activated esters etc. Suitable solvents for the acylation reaction include polar aprotic solvents, such as pyridine, etc. The reaction temperature for the acylation steps is from 0 to 30° C., and the reaction time is from 30 min to 24 h.
In the method (5) of the present invention, the compound (I) is administered together with suitable carriers and diluents. The administration may be effected via any possible route (intravenously, orally, etc.). The amount of compound (I) to be administered depends, in particular, on the patient's body weight and on the route of administration and is individually determined by the attending physician.
The invention will now be illustrated in more detail by the following Examples, which are, however, not to be construed as to limit the invention.
EXAMPLES
Example 1
Influence of N-propanoylmannosamine (Hereinafter “ManNProp”) on PC12 Cells After Stimulation with the Growth Factor NGF
It is known that stimulation with nerve growth factor (NGF) causes neuronal differentiation in PC12 cells. At an NGF concentration of 250 ng/ml and after three days of incubation, the PC12 cells already form a network of neurites.
In order to examine whether the addition of ManNProp has an influence on the neurite formation by PC12 cells, the suitable neurite lengths for different incubation times were first titrated with different NGF concentrations. At an NGF concentration of 100 ng and an incubation time of two days, the cells formed neurites whose length were double the diameter of their cell. Under such conditions, the further course of the experiments was set up.
The cells were plated with a constant number of cells on culture chambers which consisted of four chambers and were coated with collagen I (col.), poly-D-lysine (PDL) or laminin, and incubated under three different sets of conditions. Each variation was represented in duplicate.
In the first chamber, the PC12 cells were incubated with 5 mM ManNProp, and in the second chamber, they were incubated with 100 ng of NGF. In the third chamber, 100 ng of NGF plus 5 mM ManNProp was added to the cells. The first and second chambers served as a reference control for the cells under the influence of NGF and ManNProp. For each experiment, three culture chambers were sown in duplicate. After two days of incubation, the cells were fixed with paraformaldehyde, stained with crystal violet and washed with water.
For evaluation, various segments were photographed and measured according to a random choice principle. For the evaluation, only the cells stimulated with NGF which served as a control and the cells stimulated with NGF plus ManNProp were considered.
Each bar represents three experiments performed on three different days. The relative neurite length was established by CAPA (computer-assisted process analysis), and the data were integrated by means of Delta Graph.
All experiments shown here were independently performed on different days. The values from Table 1 were additionally represented graphically in FIG. 3.







TABLE 1







Enhancement of neurite growth in percent relative to the control














PDL
Col.
Laminin
sd PDL
sd Col.
sd Laminin

















0.5 mM
4
3
28
2.7
2.4
4.3


  5 mM
5
11
70
2.6
3
5.7


 25 mM
17
20
59
3.9
2.9
5.2

## Claims

1. A compound of formula




wherein R is a cyclopropylcarbonyl residue, and each R1 independently represents acyl residues.

2. A pharmaceutical composition comprising the compound according to claim 1.

3. A process for the preparation of the compound according to claim 1, comprising reacting mannosamine with an activated cyclopropylcarbonyl compound chosen from cyclopropylcarbonyl anhydrides, acid anhydrides, and activated esters to form a product wherein R and each R1 are cyclopropylcarbonyl.

4. A process for the preparation of the compound according to claim 1, comprising:
a) reacting mannosamine with an activated cyclopropylcarbonyl compound chosen from cyclopropylcarbonyl anhydrides, acid anhydrides, and activated esters to form a product;
b) purifying the product obtained in step (a);
c) saponifying the purified product obtained in step (b);
d) reacting the saponified product obtained in step (c) with an activated acyl compound chosen from activated acyl anhydrides, acid anhydrides, and activated esters, to form a compound wherein R is cyclopropylcarbonyl and R1 is an acyl unit other than cyclopropylcarbonyl.

5. A method for stimulating neurite growth, comprising administering to a mammal with A CNS-neurodegenerative disease the compound according to claim 1, wherein the CNS-neurodegenerative disease is Alzheimer's or Parkinson's disease.

6. A method of treating a mammal with a CNS-neurodegenerative disease, wherein the neurodegenerative disease is Alzheimer's or Parkinson's disease, comprising administering the compound according to claim 1.

7. A method of treating a mammal with a CNS-disease comprising administering the compound according to claim 1.

8. A method according to claim 7, wherein the CNS-neurogenerative disease is Alzheimer's disease.

9. A method according to claim 7, wherein the CNS-neurogenerative disease is Parkinson's disease.

10. A compound according to claim 1, wherein each R1 is an acyl residue chosen from acetyl, propanoyl, isopropanoyl, butanoyl, isobutanoyl, pentanoyl, isopentanoyl, hexanoyl, 2-methylbutanoyl, cyclopropylcarbonyl, crotonoyl, levulinoyl, or azidoacetyl.

11. A compound according to claim 10, wherein each R1 is acetyl.

12. A compound according to claim 10, wherein each R1 is cyclopropylcarbonyl.